TD Cowen lowered the firm’s price target on Procept BioRobotics (PRCT) to $50 from $85 and keeps a Buy rating on the shares. The firm said the stock reaction to its inline sales guidance seems overdone and the believe the company is being conservative.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRCT:
- Procept BioRobotics price target lowered to $51 from $58 at Wells Fargo
- PROCEPT BioRobotics: Hold Rating Amid Strong Revenue but Concerns Over Utilization and Sales Cycles
- Buy Rating Affirmed Amid Temporary Setbacks and Strategic Growth Prospects
- PROCEPT BioRobotics Reports Strong Q3 Growth and Optimistic 2026 Outlook
- Josh Jennings Reaffirms Buy Rating on PROCEPT BioRobotics Amid Strong Q3 Results and Conservative 2026 Forecast